Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

BACKGROUND: Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world setting. To describe the long-term effectiveness and toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Obach, Victor, Velasco, Fernando, Alvarez Escudero, Rocio, Martín Bujanda, María, Aranceta, Sonsoles, Fabregat, Neus, Marco, Teresa, Ruisanchez, Aintzine, Roncero, Natalia, Mínguez-Olaondo, Ane, Ruibal, Marta, Guisado-Alonso, Daniel, Moreira, Antia, Cuadrado-Godia, Elisa, Echeverria, Amaya, Kortazar Zubizarreta, Izaro, López-Bravo, Alba, Riesco, Nuria, González-Fernández, Lucia, Pola, Nuria, Manera, Paula, Guerrero-Peral, Ángel Luis, Oterino Duran, Agustín, González-Osorio, Yésica, Armand, Rosario, Fernández-Fernández, Santiago, García-Azorín, David, García-Moncó, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666410/
https://www.ncbi.nlm.nih.gov/pubmed/37993795
http://dx.doi.org/10.1186/s10194-023-01690-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666410/
https://www.ncbi.nlm.nih.gov/pubmed/37993795
http://dx.doi.org/10.1186/s10194-023-01690-2

Ejemplares similares